ADAGE CAPITAL PARTNERS GP, L.L.C.
Position in ELVN — Enliven Therapeutics, Inc.
CIK 1165408
Boston, MA
Position in ELVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$54,978,134
+$53,483,824 QoQ
Shares Held
1,083,313
+1384.0% QoQ
Ownership
1.48%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#17
of 210 holders
Holding Since
Jun 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ADAGE CAPITAL PARTNERS GP, L.L.C. holds $4,240,035,723 across 126 Biotechnology names. ELVN ranks #21 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
10,349,328 | $366,262,717 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
1,015,480 | $339,972,549 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
393,964 | $195,693,737 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
5,600,000 | $175,056,000 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
2,252,000 | $167,728,960 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,722,300 | $152,905,794 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
2,569,356 | $145,965,114 | |
| 8 | RPRX |
Royalty Pharma plc
|
2,500,000 | $140,175,000 |
All Filings in ELVN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $54,978,134 | 1,083,313 | Shares | Sole | 2026-08-14 | |
| 2025-09-30 | $1,494,310 | 73,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,925,760 | 96,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $8,856,000 | 450,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $14,625,000 | 650,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $20,432,000 | 800,000 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $19,630,800 | 840,000 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||